ArQule News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

14.11.18	ArQule to Present at the 30th Annual Piper Jaffray Healthcare Conference on November 28, 2018 (Businesswire)
10.11.18	Week Ahead In Pharmaceuticals: 13 Stocks To Watch (EIDX, NOVN, ZYME...) (RTTNews)
08.11.18	ArQule to Present Clinical and Preclinical Data for ARQ 751 at the 30th EORTC/AACR/NCI Symposium (Businesswire)
31.10.18	EARNINGS SUMMARY: Details of ArQule Inc. Q3 Earnings Report (RTTNews)
31.10.18	ArQule Reports Third Quarter 2018 Financial Results (Businesswire)
19.10.18	ArQule Presents Orphan Disease Clinical Data at the American Society of Human Genetics (ASHG) 2018 Annual Meeting for Its pan-AKT Inhibitor, Miransertib (ARQ 092) (Businesswire)
17.10.18	ArQule to Report Third Quarter 2018 Financial Results on October 31, 2018 (Businesswire)
04.10.18	ArQule to Present Clinical Update for Miransertib in Rare Disease at the American Society of Human Genetics (ASHG) 2018 Annual Meeting (Businesswire)
24.09.18	ArQule to Present at the Leerink Partners Roundtable Series: Rare Disease & Oncology on October 2, 2018 (Businesswire)
24.09.18	ArQule to Present at the Cantor Global Healthcare Conference on October 1, 2018 (Businesswire)
13.09.18	Miransertib (ARQ 092) Granted Fast Track Designation for the Treatment of PIK3CA-Related Overgrowth Spectrum (PROS) (Businesswire)
30.08.18	ArQule to Participate in the Annual B. Riley FBR Healthcare Conference on September 4, 2018 (Businesswire)
30.08.18	ArQule to Participate in Citi’s 13th Annual Biotech Conference on September 6, 2018 (Businesswire)
29.08.18	ArQule to Present at the 20th Annual Global Investment Conference on September 5, 2018 (Businesswire)
21.08.18	LCI Whacked On Contract Loss, CWBR Awaits Data, Busy Months Ahead For PLSE (RTTNews)
13.08.18	ArQule Announces Publication of Preclinical Data for ARQ 531, a Reversible Inhibitor of Both Wild Type and Mutant BTK (Businesswire)
02.08.18	ARQL Lifts 2018 Outlook, AXGN Q2 Revenue Up 36%, RXII Catches Eyes (RTTNews)
01.08.18	EARNINGS SUMMARY: Details of ArQule Inc. Q2 Earnings Report (RTTNews)
01.08.18	ArQule Reports Second Quarter 2018 Financial Results (Businesswire)
19.07.18	ArQule to Report Second Quarter 2018 Financial Results on August 1, 2018 (Businesswire)
13.07.18	ArQule Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares (Businesswire)
11.07.18	ArQule Announces Pricing of $60.5 Million Public Offering of Common Stock (Businesswire)
11.07.18	SCYX Takes Wings On DOVE Data, IDRA/BCRX Merger Terminated, ADXS Hits New Low (RTTNews)
10.07.18	ArQule Announces Commencement of Proposed Public Offering of Common Stock (Businesswire)
25.06.18	ArQule Added to the Russell 2000® Index (Businesswire)
15.06.18	ArQule Presents Results From Phase 1 Dose Escalation Study For ARQ 531 (RTTNews)
15.06.18	ArQule Presents Results from Ongoing Phase 1 Dose Escalation Study of its Reversible BTK Inhibitor, ARQ 531 (Businesswire)
14.06.18	ArQule to Present at The JMP Securities Life Sciences Conference on June 21, 2018 (Businesswire)
09.06.18	An Ear To The Pharma: 8 Stocks To Watch (CMRX, CRBP, KPTI, VRX…) (RTTNews)
07.06.18	ArQule to Present Clinical Data for its BTK Inhibitor, ARQ 531, at the 23rd Congress of the European Hematology Association (EHA) (Businesswire)
31.05.18	ArQule to Present at the Jefferies 2018 Healthcare Conference on June 7, 2018 (Businesswire)
24.05.18	ArQule Strengthens Executive Team with Two Key Appointments (Businesswire)
07.05.18	EARNINGS SUMMARY: Details of ArQule Inc. Q1 Earnings Report (RTTNews)
07.05.18	ArQule Reports First Quarter 2018 Financial Results (Businesswire)
23.04.18	ArQule to Report First Quarter 2018 Financial Results on May 7, 2018 (Businesswire)
18.04.18	CHEK On Watch, ARQL Inks A Deal, RTTR To Move RP-G28 Into Phase III (RTTNews)
17.04.18	ArQule, Basilea Announce License Agreement For Derazantinib - Quick Facts (RTTNews)
17.04.18	ArQule and Basilea Enter into Exclusive License Agreement for Derazantinib in the US, EU, Japan and Rest of World Excluding Greater China (Businesswire)
08.04.18	An Ear To The Pharma: 9 Stocks To Watch This Week (SELB, AGLE, BPMC, MNOV…) (RTTNews)
27.03.18	EKSO Leaps, FDA Nod For DRIO, CRVS Up 38% This Month, VTL To Report Data In Sep. (RTTNews)
22.03.18	GERN Turning Heads, ARQL To Present Data In Apr., Mark Your Calendar For PTN (RTTNews)
20.03.18	ArQule to Present at the 17th Annual Needham Healthcare Conference on March 27, 2018 (Businesswire)
16.03.18	DXR On Fire, IONS Ups Stake In AKCA, HAIR Grows, FLKS To Report Data This Month (RTTNews)
15.03.18	ArQule to Present Data at the 2018 American Association for Cancer Research (AACR) Annual Meeting (Businesswire)
05.03.18	EARNINGS SUMMARY: Details of ArQule Inc. Q4 Earnings Report (RTTNews)
05.03.18	ArQule Reports Fourth Quarter and Full Year 2017 Financial Results (Businesswire)
05.03.18	ArQule to Present at the 30th Annual Roth Conference on March 12, 2018 (Businesswire)
20.02.18	ArQule To Report Fourth Quarter 2017 Financial Results On March 5, 2018 (Businesswire)
08.02.18	ArQule to Present at The Leerink Partners 7th Annual Global Healthcare Conference on February 15, 2018 (Businesswire)
07.02.18	Roivant Sciences and ArQule Enter into License Agreement for Derazantinib in China (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

ABB	50.28	1.62 %	K V
UBS Group	28.48	1.42 %	K V
CieFinRichemont	122.70	1.24 %	K V
Lonza Grp	526.40	1.15 %	K V
Part Grp Hldg	1’280.00	1.11 %	K V
Sonova Hldg	300.80	-0.07 %	K V
Sika	228.10	-0.09 %	K V
Novartis	93.27	-0.12 %	K V
Nestle	76.48	-0.21 %	K V
Swisscom	508.50	-0.29 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu ArQule Inc.

Aktien Top/Flop

Meistgelesene Nachrichten